Premium
Tumor‐targeted and immune‐targeted monoclonal antibodies: Going from passive to active immunotherapy
Author(s) -
Marabelle Aurélien,
Gray Juliet
Publication year - 2015
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25508
Subject(s) - medicine , monoclonal antibody , immunotherapy , immune system , immune checkpoint , targeted therapy , immunology , antibody , blockade , monoclonal , cancer , oncology , cancer research , receptor
Monoclonal antibodies (mAbs) have inaugurated the concepts of tumor‐targeted therapy and personalized medicine. A new family of mAbs is currently emerging in the clinic, which target immune cells rather than cancer cells. These immune‐targeted therapies have recently demonstrated long‐term tumor responses in adults with refractory/relapsing metastatic solid tumors. Pediatric cancers are different from their adult counterparts in terms of histological features and immune infiltrates. However, the same immune checkpoint targets can be expressed within the microenvironment of pediatric tumors. The benefits of immune checkpoint blockade in pediatric cancers are currently under evaluation in early phase clinical trials. Pediatr Blood Cancer 2015;62:1317–1325. © 2015 Wiley Periodicals, Inc.